Why Is HIMS Stock Slipping Premarket Today?

• A fresh filing showed that CFO Oluyemi Okupe plans to sell up to 240,560 shares worth about $4.89 million.
• The stock had jumped over 6% Monday, marking its strongest session in a week before the insider-sale disclosure.
• The filing comes weeks after Hims launched a broad lineup of Novo Nordisk GLP-1 therapies, including multiple FDA-approved Wegovy injection and pill formulations.

Shares of Hims & Hers Health, Inc. (HIMS) slipped 1% in premarket trading after a fresh filing showed that Chief Financial Officer Oluyemi Okupe plans to sell nearly $5 million worth of stock, even as the telehealth company expands its GLP-1 weight-loss platform.

HIMS stock jumped over 6% on Monday, logging its best session in a week.

CFO Files To Sell $4.9M In Shares

According to a new filing with the U.S. Securities and Exchange Commission (SEC), Okupe intends to sell up to 240,560 shares of Hims & Hers common stock with an estimated aggregate market value of about $4.89 million as part of a pre-arranged Rule 10b5-1 trading plan tied to compensation-linked stock awards. 

The insider filing comes weeks after Hims & Hers announced plans to launch a broad lineup of Novo Nordisk GLP-1 medications on its platform, including FDA-approved Wegovy injection and pill-based formulations across multiple dose levels.

Eligible patients will be able to access Wegovy injection doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, along with pill formulations in 1.5 mg, 4 mg, 9 mg and 25 mg, with a 7.2 mg injection expected later. The platform will also offer Ozempic injection pens in 0.25 mg, 0.5 mg, 1 mg and 2 mg doses for Type 2 diabetes management.

The rollout follows Novo Nordisk’s decision earlier this month to drop its patent-infringement lawsuit against Hims & Hers, which was tied to the company’s earlier compounded version of a Wegovy-style pill priced at $49 per month.

Instead, the companies reached an arrangement allowing Hims & Hers to transition patients to FDA-approved GLP-1 treatments while discontinuing the marketing of compounded alternatives.

Regulatory Spotlight Returns To Compounded Peptides

The GLP-1 expansion comes alongside a broader regulatory debate over peptide therapies after federal health officials reportedly signaled that the FDA may revisit restrictions on certain injectable peptides that were previously removed from compounding eligibility lists due to safety concerns.

In 2023, the agency removed 14 peptides from the list of compounds pharmacies could legally produce for individualized patient use after observing growing marketing claims about anti-aging and performance benefits that lacked supporting clinical evidence.

How Do Retail Traders Feel About HIMS?

On Stocktwits, retail sentiment for HIMS was ‘bearish’ amid ‘extremely low’ message volume.

One user noted the CFO’s stock sale filing and said, “They [Hims] have no intention of protecting the company and clearly see shareholders as fools.”

Another user said, “buy buy buy! 10x stock.”

HIMS stock has declined 37% year-to-date.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: UNH Vs. HUM: Which Insurer Stock Has More Upside After CMS Reverses Wall Street’s Biggest Medicare Rate Fear?